Its bovine genetics business sells dairy and beef bull semen and embryos from superior cattle for artificial insemination, while its porcine genetics business sells genetically superior breeding pigs and semen to farmers. Growth in the porcine division and strategic partnerships in China are expected to enhance revenue and earnings, while expansion in the bovine segment through acquisitions is projected to improve profit margins and financial stability.
Cyborg Score Rationale
Genus exceeded the UK Biotech industry which returned 43.1% over the past year, and exceeded the UK Market which returned 23.9%. Strategic growth drivers include porcine expansion, China partnerships, and leadership in advanced genetics positioning for margin expansion and premium pricing.
Top Insights
Market cap of £1.70b with 66.41m shares outstanding; shares traded in 12-month range of 1,424p-3,220p
Two primary revenue drivers: bovine genetics (ABS) and porcine genetics (PIC) operating globally across 70+ countries
Strategic focus on China expansion and PRRS-resistant pig commercialization for growth and market penetration
Risks from alternative protein trends and heavy R&D dependence; complex regulatory environment adds margin pressure
Named Competitors
Genomic breeding solutions — Traditional livestock breeding genetics providers
Recent Developments
(Feb 2026) Expansion in porcine business and PRRS resistant pig commercialization boost revenue stability
(2026) Strategic partnerships in China and emerging market advancement driving revenue growth expectations
(2025) Company dividend yield at 1.02-1.56% with broker consensus Buy recommendation
Open the full interactive Genus plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.